Boston Scientific Acquires Lumenis Surgical Business from Baring Private Equity Asia for $1.07B

Boston Scientific To Acquire Penumbra, Inc. for About $14.5 Billion

January 16, 2026

Medical Devices

Boston Scientific signed a definitive agreement to acquire Penumbra, Inc. in a cash-and-stock transaction valued at about $14.5 billion on an enterprise value basis. The deal is designed to broaden Boston Scientific’s vascular and neurovascular portfolio, particularly in mechanical thrombectomy and adjacent neurovascular markets, with expected closing in 2026 subject to regulatory approvals and Penumbra shareholder approval.

Boston Scientific Agrees to Acquire Bolt Medical

January 8, 2025

Medical Devices

Boston Scientific Corporation entered into a definitive agreement to acquire Bolt Medical, Inc., developer of an intravascular lithotripsy (IVL) laser-based platform for treating calcified coronary and peripheral artery disease. The deal includes an upfront payment of about $443 million for the 74% stake Boston Scientific does not already own, plus up to $221 million tied to regulatory milestones.

Boston Scientific to Acquire Apollo Endosurgery for $615 Million

November 30, 2022

Medical Devices

Boston Scientific Corporation has entered into a definitive agreement to acquire Apollo Endosurgery for $615 million in cash (approximately $10 per share). The deal expands Boston Scientific’s endoluminal surgery (ELS) capabilities and adds an adjacency into the endobariatric market.

Boston Scientific Acquires Baylis Medical Company Inc.

October 6, 2021

Medical Devices

Boston Scientific Corporation entered into a definitive agreement to acquire Baylis Medical Company Inc. for an upfront payment of $1.75 billion, subject to closing adjustments. The acquisition is expected to expand Boston Scientific’s electrophysiology and structural heart portfolios by adding the RF NRG and VersaCross transseptal platforms and related guidewires, sheaths, and dilators.

Boston Scientific Acquires BTG plc

August 19, 2019

Medical Devices

Boston Scientific Corporation completed its acquisition of BTG plc by scheme of arrangement, with BTG shareholders receiving 840 pence in cash per share. The purchase brings BTG’s interventional medicine portfolio, specialty pharmaceuticals and licensing business into Boston Scientific, strengthening its capabilities in interventional oncology and vascular therapies.

Boston Scientific Acquires Xlumena

April 1, 2015

Medical Devices

Boston Scientific agreed to acquire Mountain View–based medical device company Xlumena, gaining the AXIOS and HOT AXIOS stent and delivery systems. The deal includes $62.5 million upfront, $12.5 million contingent on FDA clearance of HOT AXIOS and additional sales-based milestones, and is intended to expand Boston Scientific's endoscopy and EUS therapeutic capabilities and accelerate global commercialization of the AXIOS platform.